Risks for Anaphylaxis With Intravenous Iron Formulations

Affiliations

¹ Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, and Department of Veterans Affairs New Jersey Health Care System, New Brunswick, Piscataway, and East Orange, New Jersey.
² Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York.
³ Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
⁴ Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Medicine, Rutgers Robert Wood Johnson Medical School, and Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick and Piscataway, New Jersey.

Comment

Chintan V Dave et al. Ann Intern Med. 2022 Nov.

. 2022 Nov;175(11):W143-W144.

doi: 10.7326/L22-0283.

¹ Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, and Department of Veterans Affairs New Jersey Health Care System, New Brunswick, Piscataway, and East Orange, New Jersey.
² Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York.
³ Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
⁴ Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Medicine, Rutgers Robert Wood Johnson Medical School, and Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick and Piscataway, New Jersey.

No abstract available

Comment on

Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study.
Dave CV, Brittenham GM, Carson JL, Setoguchi S. Dave CV, et al. Ann Intern Med. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. Epub 2022 Mar 29. Ann Intern Med. 2022. PMID: 35344378
Risks for Anaphylaxis With Intravenous Iron Formulations.
Al-Samkari H, Glaspy JA, Means RT Jr, Chertow GM, Auerbach M. Al-Samkari H, et al. Ann Intern Med. 2022 Nov;175(11):W143. doi: 10.7326/L22-0282. Ann Intern Med. 2022. PMID: 36375165 No abstract available.